& Ovarian cancer pectus
Si pectus et cancer ovarii aegrotus es, invenias te esse cancrum BRCA1/2 mutationis post testem geneticam transiens, et vita tua salvatur. Secundum Oncologist Global Network, Niraparib, medicamento iaculis in gene PARP iaculis, in quarta parte huius anni venalicium exhibebitur propter mirabilem periodum III orci iudicii eventum. Ob mirabilem probationem clinicam notitiae huius medicamento, certum esse certum est medicamentum FDA probatum iri. Scopum medicamento evolutionis societatis Tesaro pretio comparavit ab $37 ad $77 statim propter hoc breakthrough.
Quod genus medicamenti Niraparib?
It is an oral targeted drug that targets the PARP gene and is not effective for any cancer. It mainly targets cancers with mutations in the BRCA1 / 2 gene, such as ovarian cancer and breast cancer. It reflects the “precision treatment” concept of modern medicine. Patients with ovarian and pectus cancer need genetic testing to find out if they have a BRCA1 / 2 mutation.
Quam mirabile est curatio Niraparib?
Tesaro Phase III clinicae notitiae Niraparib propter aegros ovarii ovarii relapsos post chemotherapyam progressam dimisit. Eventus ostendit pro motu ovarii cum BRCA generum, Niraparib viva voce semel cottidie sumptum esse, et morbus mediocris liberorum superstes fuit 21 mensuum, cum coetus moderatus (aegri soli chemotherapy) progressum liberorum superesset 5.5 mensuum. . 21 menses vs 5.5 menses superesset tempus prope 4 tempora longior! Haec figura nimis terribilis est, quod diuturna medicamenta ex novis rebus maxime paucis mensibus superstite sunt. Aliis verbis, aegris mutationum BRCA qui Niraparib utuntur, supervivere possunt in mediocris plus quam 21 menses. Hoc valde mirabile est aegris cum cancro ovarii recurrente progresso.
Quod genus cancer Niraparib tractare potest?
PARP et BRCA sunt duo genera praecipua emendandi DNA mutationum in cellis responsabiles, et "dextra et sinistra methodus tutelae" sunt ad custodiam cellarum salutem. Ob influentiam ambitus, DNA mutationes in corpore nostro quolibet tempore occurrunt, alicubi, sed ob exsistentiam horum duorum modorum tutelae, post DNA mutationes praestatur, plus quam 99.9999% melius reparari potest, alioquin incidentia cancri. multo altior erit quam nunc.
Sed nonnullis, ob causas innatas vel acquisitas, ipsa cellula BRCA gene mutatur et suam actionem amittit, ita probabilitas post DNA mutationem reparationis valde debilitatur, et plures mutationes gene cito accumulabuntur. Probabilitas cancri in hoc coetu vehementer augetur.
Although PARP inhibitors are mainly targeted at breast and ovarian cancer, some patients with other cancers also carry BRCA mutations or other DNA repair defects. They theoretically use PARP-targeted drugs to work well, including some carcinomata prostatae. , Fallopian tube cancer, pancreatic cancer, childhood myeloid leukemia anguli, etc. Clinical trials for these cancers are ongoing, and the world is waiting to see the results.
